{"DataElement":{"publicId":"7307764","version":"1","preferredName":"Disease Status NCCN ALL Response Criterion Blood And Bone Marrow Type","preferredDefinition":"A description of the NCCN ALL disease response criteria for blood and bone marrow.","longName":"DIS_NCCN_ALL_RSP_CRT_BL_BM_TY","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"2512861","version":"1","preferredName":"Disease or Disorder Status","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time.","longName":"2404658v1.0:2320064v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320064","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037B-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B898979-184A-3A90-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7307758","version":"1","preferredName":"NCCN ALL Response Criterion Blood And Bone Marrow Type","preferredDefinition":"An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology._Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison._A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes._Something distinguishable as an identifiable class based on common qualities.","longName":"NCCN_ALL_RSP_CRT_BLD_BM_TY","context":"DCI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Assessed","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A69F584C-27DE-31CF-E053-4EBD850A8BBD","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"NCCN ALL Response Criteria for Blood and Bone Marrow Relapsed Disease","ValueMeaning":{"publicId":"7307760","version":"1","preferredName":"NCCN ALL Response Criteria for Blood and Bone Marrow Relapsed Disease","longName":"7307760","preferredDefinition":"Reappearance of blasts in the blood or bone marrow (greater than 5 percent) or in any extramedullary site after complete remission. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN ALL Response Criteria for Blood and Bone Marrow Relapsed Disease","conceptCode":"C172173","definition":"Reappearance of blasts in the blood or bone marrow ( greater than 5 percent) or in any extramedullary site after complete remission. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A69F584C-27EA-31CF-E053-4EBD850A8BBD","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A69F584C-2803-31CF-E053-4EBD850A8BBD","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"Refractory","valueDescription":"NCCN ALL Response Criteria for Blood and Bone Marrow Refractory Disease","ValueMeaning":{"publicId":"7307761","version":"1","preferredName":"NCCN ALL Response Criteria for Blood and Bone Marrow Refractory Disease","longName":"7307761","preferredDefinition":"Failure to achieve complete remission at the end of induction. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN ALL Response Criteria for Blood and Bone Marrow Refractory Disease","conceptCode":"C172172","definition":"Failure to achieve complete remission at the end of induction. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A69F584C-280F-31CF-E053-4EBD850A8BBD","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A69F584C-2828-31CF-E053-4EBD850A8BBD","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"PD","valueDescription":"NCCN ALL Response Criteria for Blood and Bone Marrow Progressive Disease","ValueMeaning":{"publicId":"7307762","version":"1","preferredName":"NCCN ALL Response Criteria for Blood and Bone Marrow Progressive Disease","longName":"7307762","preferredDefinition":"Increase of at least 25 percent in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN ALL Response Criteria for Blood and Bone Marrow Progressive Disease","conceptCode":"C172171","definition":"Increase of at least 25 percent in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A69F584C-2834-31CF-E053-4EBD850A8BBD","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A69F584C-284D-31CF-E053-4EBD850A8BBD","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"CRi","valueDescription":"NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission with Incomplete Blood Count Recovery","ValueMeaning":{"publicId":"7307763","version":"1","preferredName":"NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission with Incomplete Blood Count Recovery","longName":"7307763","preferredDefinition":"Meets all criteria for NCCN ALL complete response except platelet count or ANC. (Adapted from NCCN Guidelines, Version 1.2020, February 20,2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission with Incomplete Blood Count Recovery","conceptCode":"C172170","definition":"Meets all criteria for NCCN ALL complete response except platelet count or ANC. (Adapted from NCCN Guidelines, Version 1.2020, February 20,2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A69F584C-2859-31CF-E053-4EBD850A8BBD","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A69F584C-2872-31CF-E053-4EBD850A8BBD","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"CR","valueDescription":"NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission","ValueMeaning":{"publicId":"7307759","version":"1","preferredName":"NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission","longName":"7307759","preferredDefinition":"No circulating lymphoblasts or extramedullary disease, trilineage hematopoiesis (TLH) and less than 5 percent blasts, ANC greater than 1,000 per microL, platelets greater than 100,000 per microL, no recurrence for 4 weeks. (Adapted from NCCN Guidelines, Version 1.2020, February 20,2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission","conceptCode":"C172169","definition":"No circulating lymphoblasts or extramedullary disease, trilineage hematopoiesis (TLH) and less than 5 percent blasts, ANC greater than 1,000 per microL, platelets greater than 100,000 per microL, no recurrence for 4 weeks. (Adapted from NCCN Guidelines, Version 1.2020, February 20,2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A3853D-AD52-7816-E053-4EBD850A13B3","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6A3853D-AD6B-7816-E053-4EBD850A13B3","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7307757","version":"1","preferredName":"National Comprehensive Cancer Network Acute Lymphoblastic Leukemia Disease Response Criterion Blood And Bone Marrow Type","preferredDefinition":"An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology.:Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.:That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.:A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.:An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.:The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.:Something distinguishable as an identifiable class based on common qualities.","longName":"7307757v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Comprehensive Cancer Network","conceptCode":"C39471","definition":"An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Criterion","conceptCode":"C25466","definition":"That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Blood","conceptCode":"C12434","definition":"A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bone Marrow","conceptCode":"C12431","definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A3853D-AD2B-7816-E053-4EBD850A13B3","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A3853D-AD3C-7816-E053-4EBD850A13B3","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"KUMMEROA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Acute Lymphoblastic Leukemia","type":"Preferred Question Text","description":"Acute Lymphoblastic Leukemia Response Criteria for Blood and Bone Marrow","url":null,"context":"DCI"}],"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A3AD22-4CE9-7C18-E053-4EBD850AD3D2","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"KUMMEROA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}